A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
Completed · Phase 4
Conditions studied: Multiple Sclerosis
In brief
The primary objective is to assess the pharmacokinetic (PK) profile of natalizumab (Tysabri) at steady state. The secondary objective is to assess the pharmacodynamics (PD) profile (α4 integrin saturation) of Tysabri at steady state.
Key facts
- Study ID
- NCT00744679
- Run by
- Biogen
- People needed
- 20
- Starts
- 2008-11-01
- Expected to finish
- 2008-12-01
- Last updated by the study team
- 2015-02-10
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Latham, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.